PERSONALIZED CELL THERAPY MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America dominates the global personalized cell therapy market, with an estimated market share of 38.2% in 2024, due to significant industry presence and extensive research activities. American biotechnology and pharmaceutical companies have pioneered numerous cell therapy innovations over the past few decades. Major market players like Novartis, Gilead Sciences, and Juno Therapeutics have their headquarters in the U.S.

Moreover, large population size and higher healthcare expenditure in the U.S. translate to a sizable patient pool requiring cutting-edge treatments. Personalized cell therapies have found numerous clinical applications in oncology, cardiology, neurology and other therapeutic areas in the country. Support from the National Institutes of Health and the Food and Drug Administration has accelerated research and development as well as expedited approval processes for advanced therapies.

Asia Pacific is expected to be the fastest growing regional market for personalized cell therapies. Countries like China, Japan, South Korea and India are emerging as attractive destinations for outsourced clinical research and manufacturing capabilities. Rising affordability of novel drugs alongside growing medical infrastructure and awareness will fuel the mass adoption of personalized medicine in Asia in the near future.